As previously announced, on April 30, 2016, NephroGenex, Inc. (the
Company) filed a voluntary petition for relief (the Chapter 11
Filing) under Chapter 11 of Title 11 of the United States Code (the
Bankruptcy Code) in the United States Bankruptcy Court for the
District of Delaware (the Bankruptcy Court).

On May 24, 2017, the Company filed its monthly operating report for
the period of May 1, 2017 through May 24, 2017 (the Monthly
Operating Report) with the Bankruptcy Court. The Monthly Operating
Report is attached to this Current Report on Form 8-K as Exhibit
99.1.

Cautionary Statements Regarding the Monthly Operating Report

The Company cautions investors and potential investors not to place
undue reliance upon the information contained in the Monthly
Operating Report, which was not prepared for the purpose of
providing the basis for an investment decision relating to any of
the securities of the Company. The Monthly Operating Report is
limited in scope and has been prepared solely for the purpose of
complying with requirements of the Bankruptcy Court. The Monthly
Operating Report was not reviewed by independent accountants, is in
a format prescribed by applicable bankruptcy laws, and is subject
to future adjustment. The financial information in the Monthly
Operating Report was not prepared in accordance with accounting
principles generally accepted in the United States (GAAP) and,
therefore, may exclude items required by GAAP, such as certain
reclassifications, non-cash items, accruals, valuations and
disclosures. The Monthly Operating Report also contains information
for periods which are different from the historical periods
required in the Companys reports to the Securities Exchange Act of
1934, as amended (the Exchange Act), and such information might not
be indicative of the Company’s financial condition or operating
results for a period that would be reflected in the Company’s
financial statements or its reports to the Exchange Act.
Information set forth in the Monthly Operating Report should not be
viewed as indicative of future results.

Cautionary Statements Regarding Forward-Looking Statements

This current report on Form 8-K and Exhibit 99.1 hereto contain
certain statements that may be deemed to be forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933 and Section 21E of the Securities Exchange Act of 1934. In
some cases, these forward-looking statements can be identified by
the use of forward-looking terminology, including the terms
believes, estimates, anticipates, expects, plans, intends, may,
could, might, will, should, approximately or, in each case, their
negative or other variations thereon or comparable terminology,
although not all forward-looking statements contain these words.
They appear in a number of places throughout this current report on
Form 8-K and Exhibit 99.1 hereto and include statements regarding
our intentions, beliefs, projections, outlook, analyses or current
expectations concerning, among other things, the strength and
breadth of our intellectual property, expectations regarding
financial condition, liquidity, the length of time that we will be
able to continue to fund our operating expenses, capital
expenditures and our previously announced bankruptcy proceeding.

By their nature, forward-looking statements involve risks and
uncertainties because they relate to events, competitive dynamics,
and healthcare, regulatory and scientific developments and depend
on the economic circumstances that may or may not occur in the
future or may occur on longer or shorter timelines than
anticipated. Although we believe that we have a reasonable basis
for each forward-looking statement contained herein, we caution you
that forward-looking statements are not guarantees of future
performance and that our actual results of operations, financial
condition and liquidity, and the development of the industry in
which we operate may differ materially from the forward-looking
statements contained in the presentation as a result of, among
other factors, the factors referenced in the Risk Factors section
of our Annual Report on Form 10-K filed with the Securities and
Exchange Commission during March 2016. Any forward-looking
statements that we make herein speak only as of the date of such
statement, and we undertake no obligation to update such statements
to reflect events or circumstances after the date of the
presentation, except as required by law.

You should read carefully our Cautionary Note Regarding
Forward-Looking Statements and Industry Data and the factors
described in the Risk Factors sections of our Annual Report on Form
10-K to better understand the risks and uncertainties inherent in
our business.

Additional Information Regarding the Chapter 11 Filing

Information about the Chapter 11 process, as well as court filings
and other documents related to the reorganization proceedings, is
available through the Companys claims agent, Kurtzman Carson
Consultants LLC, at www.kccllc.net/NephroGenex. Information
contained on, or that can be accessed through, such web site or the
Bankruptcy Courts web site is not part of this Current Report.

Limitation on Incorporation by Reference

In accordance with General Instruction B.2 of Form 8-K, the
information in this Item 7.01 is being furnished for informational
purposes only and shall not be deemed filed for purposes of Section
18 of the Exchange Act, or otherwise subject to the liabilities of
that section, nor shall such information be deemed incorporated by
reference in any filing under the Securities Act of 1933, as
amended, except as otherwise expressly stated in such filing. The
filing of this current report (including Exhibit 99.1 attached
hereto) will not be deemed an admission as to the materiality of
any information required to be disclosed solely by Regulation FD.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.